Breast Cancer HR+ - Dr. Stephanie Graff

August 23, 2024
Algorithms Breast Cancer 2022

Key Points

NATALEE Phase III study of ribociclib (RIBO) + endocrine therapy (ET) in HR+ patients
SONIA challenging the need for first-line use of a CDK4/6 Inhibitor in HR+ advanced breast cancer patients
X-7/7 trial evaluating fixed-dose capecitabine compared to standard dose capecitabine in metastatic breast cancer
Dr. Stephanie Graff
Profile

Discussing Breast Cancer ASCO 2023 Highlights

Focusing on practice-changing studies with Dr. Stephanie Graff, Director of Breast Oncology, Associate Professor of Medicine, Lifespan Cancer Institute, Brown University. Covering three important studies

Tags:
Dr. Stephanie Graff Breast Cancer HR+

Related Posts